These findings suggest that the activation of EphA4-ephexin1 signaling in the PFC plays a key role in the pathophysiology of depression, thereby indicating that EphA4-ephexin1 signaling could be a novel therapeutic target for depression. This evidence concerns the gene EPHA4 and depressive symptom measurement.